Dendreon said that it no longer expects sales of its prostate cancer therapy Provenge to grow in 2013, and the company's shares slumped 13 percent in aftermarket trading. Net sales of Provenge decreased 8 percent in the second quarter and Dendreon's revenue from the drug fell 13 percent in the first half of the year.
Shares of Dendreon Corp. moved higher Monday after the company said sales of its prostate cancer...
WASHINGTON (AP) — Shares of biotech developer Dendreon Corp. rose Friday after health insurer...
NEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.
WASHINGTON (AP) — Shares of biotech drugmaker Dendreon fell today on worries about an investigation into company conduct by financial regulators.
Dendreon tumbled more than 12 percent in premarket trading Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.
Dendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.
SEATTLE (AP) — Dendreon Corp. said Thursday that it will eliminate 500 jobs, or more than a quarter of its work force, as it reduces costs to compensate for disappointing sales of its prostate cancer therapy Provenge.